The addition of an anti-Ly6G blocking antibody to anti-PD-1/CTLA-4 therapy effectively reversed treatment resistance and restored CD8+T cell activity in lung cancer models, by targeting Ly6G on neutrophils [186]. The gene discussed is CD8A; the disease is lung cancer.